Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin lambda joining 2 (IGLJ2) is a gene segment within the immunoglobulin lambda locus on chromosome 22 that encodes one of the multiple joining (J) segments contributing to the diversity of immunoglobulin lambda light chains in B cells[1][3][7]. During B cell development, the IGLJ2 gene segment can be recombined with a variable (V) segment to form the variable region of the lambda light chain, one of the two main immunoglobulin light chain types[1][6]. This V-J recombination is a crucial step in the process that generates the vast diversity required for effective antigen recognition by antibodies[2]. IGLJ2 is not a protein-coding gene in the typical sense but is a functional joining gene segment essential for the assembly of antibody light chains[7]. It is not considered a therapeutic target itself, as it does not form a receptor, enzyme, or classical drug target, but is instead integral to the genetic mechanisms underlying antibody diversity in the adaptive immune system[3][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin lambda joining 2 (IGLJ2).